PRA Health Sciences Inc (PRAH) Analysts See $0.81 EPS

October 13, 2017 - By Marguerite Chambers

 PRA Health Sciences Inc (PRAH) Analysts See $0.81 EPS

Investors wait PRA Health Sciences Inc (NASDAQ:PRAH) to report on November, 1. its quarterly earnings Wall Street analysts expect $0.81 EPS, up $0.19 or 30.65 % from last year’s $0.62 same quarter earnings. This translates into $50.71 million profit for PRAH giving the stock a 25.34 P/E. This is assuming the current $0.81 EPS is accurate. PRA Health Sciences Inc’s Wall Street analysts see 30.65 % EPS growth, taking into account the $0.62 EPS reproted in the previous quarter, The stock increased 0.82% or $0.67 during the last trading session, reaching $82.11. About 338,886 shares traded. PRA Health Sciences Inc (NASDAQ:PRAH) has risen 52.22% since October 13, 2016 and is uptrending. It has outperformed by 35.52% the S&P500.

PRA Health Sciences Inc (NASDAQ:PRAH) Ratings Coverage

Among 12 analysts covering PRA Health Sciences (NASDAQ:PRAH), 8 have Buy rating, 0 Sell and 4 Hold. Therefore 67% are positive. PRA Health Sciences had 23 analyst reports since July 22, 2015 according to SRatingsIntel. As per Monday, March 28, the company rating was upgraded by SunTrust. The firm has “Overweight” rating by KeyBanc Capital Markets given on Monday, June 13. Robert W. Baird maintained the stock with “Outperform” rating in Tuesday, August 8 report. The rating was maintained by Jefferies on Monday, September 11 with “Buy”. The stock of PRA Health Sciences Inc (NASDAQ:PRAH) has “Neutral” rating given on Tuesday, June 21 by Credit Suisse. The stock has “Buy” rating by Jefferies on Thursday, June 1. The firm has “Neutral” rating given on Thursday, November 19 by Suntrust Robinson. First Analysis initiated the shares of PRAH in report on Tuesday, June 21 with “Equal-Weight” rating. Credit Suisse reinitiated PRA Health Sciences Inc (NASDAQ:PRAH) on Friday, August 14 with “Outperform” rating. SunTrust initiated the shares of PRAH in report on Thursday, November 19 with “Neutral” rating.

PRA Health Sciences, Inc. is a contract research organization. The company has market cap of $5.14 billion. The Firm provides outsourced clinical development services to the biotechnology and pharmaceutical industries. It has a 53.38 P/E ratio. The Firm offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

More notable recent PRA Health Sciences Inc (NASDAQ:PRAH) news were published by: Globenewswire.com which released: “PRA Health Sciences, Inc. Reports Second Quarter 2017 Results and Updates Full …” on August 07, 2017, also Seekingalpha.com with their article: “PRA Health Sciences Set For A Quarterly Earnings Surprise – Again” published on July 26, 2017, Nasdaq.com published: “Pra Health Sciences Inc (PRAH) President & CEO Colin Shannon Sold $29.9 …” on August 16, 2017. More interesting news about PRA Health Sciences Inc (NASDAQ:PRAH) were released by: Globenewswire.com and their article: “PRA Health Sciences Named Clinical Research Company of the Year” published on May 02, 2017 as well as Seekingalpha.com‘s news article titled: “PRA Health Sciences’ (PRAH) CEO Colin Shannon on Q1 2017 Results – Earnings …” with publication date: April 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.